Pulmonary Fibrosis - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 377
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P9D6736F6CAEN
Leaflet:

Download PDF Leaflet

Pulmonary Fibrosis - Pipeline Review, H2 2016
Pulmonary Fibrosis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
  • The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Pulmonary Fibrosis Overview
Therapeutics Development
Pulmonary Fibrosis - Therapeutics under Development by Companies
Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
Pulmonary Fibrosis - Pipeline Products Glance
Pulmonary Fibrosis - Products under Development by Companies
Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
Pulmonary Fibrosis - Companies Involved in Therapeutics Development
Pulmonary Fibrosis - Therapeutics Assessment
Drug Profiles
Pulmonary Fibrosis - Dormant Projects
Pulmonary Fibrosis - Discontinued Products
Pulmonary Fibrosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Pulmonary Fibrosis, H2 2016
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Development by Companies, H2 2016 (Contd.3)
Number of Products under Development by Companies, H2 2016 (Contd.4)
Number of Products under Development by Companies, H2 2016 (Contd.5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Development by Companies, H2 2016 (Contd.4)
Products under Development by Companies, H2 2016 (Contd.5)
Products under Development by Companies, H2 2016 (Contd.6)
Products under Development by Companies, H2 2016 (Contd.7)
Products under Investigation by Universities/Institutes, H2 2016
Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016
Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016
Pulmonary Fibrosis - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2016
Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2016
Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016
Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2016
Pulmonary Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016
Pulmonary Fibrosis - Pipeline by Clanotech AB, H2 2016
Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H2 2016
Pulmonary Fibrosis - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016
Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H2 2016
Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2016
Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2016
Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2016
Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016
Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by GNI Group Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2016
Pulmonary Fibrosis - Pipeline by Hydra Biosciences, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Immunomet Therapeutics, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Inventiva, H2 2016
Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016
Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2016
Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2016
Pulmonary Fibrosis - Pipeline by KineMed, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by Lpath, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Lung Therapeutics, Inc, H2 2016
Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2016
Pulmonary Fibrosis - Pipeline by NicOx S.A., H2 2016
Pulmonary Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016
Pulmonary Fibrosis - Pipeline by Novartis AG, H2 2016
Pulmonary Fibrosis - Pipeline by Nuevolution AB, H2 2016
Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
Pulmonary Fibrosis - Pipeline by Pharmicell Co., Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by RedHill Biopharma Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H2 2016
Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H2 2016
Pulmonary Fibrosis - Pipeline by Sanofi, H2 2016
Pulmonary Fibrosis - Pipeline by Sirnaomics, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H2 2016
Pulmonary Fibrosis - Pipeline by Symic Biomedical, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by Terpenoid Therapeutics, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Vault Pharma Inc., H2 2016
Pulmonary Fibrosis - Pipeline by Vericel Corporation, H2 2016
Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H2 2016
Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pulmonary Fibrosis - Dormant Projects, H2 2016
Pulmonary Fibrosis - Dormant Projects (Contd.1), H2 2016
Pulmonary Fibrosis - Dormant Projects (Contd.2), H2 2016
Pulmonary Fibrosis - Dormant Projects (Contd.3), H2 2016
Pulmonary Fibrosis - Dormant Projects (Contd.4), H2 2016
Pulmonary Fibrosis - Dormant Projects (Contd.5), H2 2016
Pulmonary Fibrosis - Dormant Projects (Contd.6), H2 2016
Pulmonary Fibrosis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Pulmonary Fibrosis, H2 2016
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

AdAlta Pty Ltd.
Advinus Therapeutics Ltd
Aeolus Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc.
Angion Biomedica Corp.
Apellis Pharmaceuticals Inc
Asahi Kasei Pharma Corp.
aTyr Pharma, Inc.
Biogen Inc
Bioneer Corporation
BiOrion Technologies B.V.
Bristol-Myers Squibb Company
Celgene Corporation
Chrysalis Pharma SAS
Clanotech AB
Compugen Ltd.
Cynata Therapeutics Limited
Diffusion Pharmaceuticals Inc.
Digna Biotech, S.L.
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
FibroStatin SL
Galapagos NV
Galectin Therapeutics, Inc.
GenKyoTex S.A.
GlaxoSmithKline Plc
Global Blood Therapeutics, Inc.
GNI Group Ltd.
HEC Pharm Co., Ltd.
Histocell S.L.
Hydra Biosciences, Inc.
iBio, Inc.
Immunomet Therapeutics, Inc.
Inventiva
Isarna Therapeutics GmbH
Kadmon Corporation, LLC
Kasiak Research Private Limited
KineMed, Inc.
Kolltan Pharmaceuticals, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lpath, Inc.
Lung Therapeutics, Inc
miRagen Therapeutics, Inc.
Moerae Matrix, Inc.
MorphoSys AG
NicOx S.A.
Nitto Denko Corporation
Novartis AG
Nuevolution AB
Pharmaxis Limited
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
Promedior, Inc.
ProMetic Life Sciences Inc.
Pulmatrix, Inc.
RedHill Biopharma Ltd.
Respira Therapeutics Inc
Rhizen Pharmaceuticals S.A.
Ribomic Inc.
Saje Pharma, LLC
Sanofi
Sirnaomics, Inc.
Sorrento Therapeutics, Inc.
SPR Biosciences LLC
Symic Biomedical, Inc.
TaiwanJ Pharmaceuticals Co., Ltd.
Terpenoid Therapeutics, Inc.
Teva Pharmaceutical Industries Ltd.
Therabron Therapeutics, Inc.
Vault Pharma Inc.
Vericel Corporation
Vicore Pharma AB
Yuhan Corporation
Skip to top


Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 260 pages
Cystic Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 389 pages

Ask Your Question

Pulmonary Fibrosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: